All information products included in https://us-cert.cisa.gov/ics are provided "as is" for informational purposes only. The Department of Homeland Security (DHS) does not provide any warranties of any kind regarding any information contained within. DHS does not endorse any commercial product or service, referenced in this product or otherwise. Further dissemination of this product is governed by the Traffic Light Protocol (TLP) marking in the header. For more information about TLP, see https://us-cert.cisa.gov/tlp/.
1. EXECUTIVE SUMMARY
- CVSS v3 5.3
- ATTENTION: Exploitable remotely/low skill level to exploit
- Vendor: Philips
- Equipment: DreamMapper
- Vulnerability: Insertion of Sensitive Information into Log File
2. RISK EVALUATION
Successful exploitation of this vulnerability could allow an attacker access to the log file information containing descriptive error messages.
3. TECHNICAL DETAILS
3.1 AFFECTED PRODUCTS
The following versions of DreamMapper, a mobile app used to manage sleep apnea, are affected:
- DreamMapper Version 2.24 and prior
3.2 VULNERABILITY OVERVIEW
Information written to log files can give guidance to a potential attacker.
- CRITICAL INFRASTRUCTURE SECTORS: Healthcare and Public Health
- COUNTRIES/AREAS DEPLOYED: Worldwide
- COMPANY HEADQUARTERS LOCATION: Netherlands
Lutz Weimann, Tim Hirschberg, Issam Hbib, and Florian Mommertz of SRC Security Research & Consulting GmbH reported this vulnerability to the Federal Office for Information Security (BSI), Germany, in the context of the BSI project eCare – Digitization in care reported this to Philips.
Philips plans a new release for the DreamMapper app by June 30, 2021, that remediates this vulnerability.
Users with questions regarding their specific Philips DreamMapper installations should contact a Philips service support team or regional service support.
The Philips advisory is available at the following URL: http://www.philips.com/productsecurity
Please see the Philips product security website for the latest security information for Philips products:
CISA recommends users take defensive measures to minimize the risk of exploitation of this vulnerability. Specifically, users should:
- Implement physical security measures to limit or control access to critical systems.
- Restrict system access to authorized personnel only and follow a least privilege approach.
- Apply defense-in-depth strategies.
- Disable unnecessary accounts and services.
- Where additional information is needed, refer to existing cybersecurity in medical device guidance issued by the FDA.
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage on us-cert.gov. Several recommended practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage on us-cert.gov in the Technical Information Paper, ICS-TIP-12-146-01B--Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing any suspected malicious activity should follow their established internal procedures and report their findings to CISA for tracking and correlation against other incidents.
No known public exploits specifically target this vulnerability.
For any questions related to this report, please contact the CISA at:
Toll Free: 1-888-282-0870
CISA continuously strives to improve its products and services. You can help by choosing one of the links below to provide feedback about this product.
Please share your thoughts.
We recently updated our anonymous product survey; we'd welcome your feedback.